194 related articles for article (PubMed ID: 30055660)
21. Imaging characteristics and safety of florbetapir (¹⁸F) in Japanese healthy volunteers, patients with mild cognitive impairment and patients with Alzheimer's disease.
Namiki C; Takita Y; Iwata A; Momose T; Senda M; Okubo Y; Joshi AD; Lu M; Agbulos A; Breault C; Pontecorvo MJ
Ann Nucl Med; 2015 Aug; 29(7):570-81. PubMed ID: 25943346
[TBL] [Abstract][Full Text] [Related]
22. The diagnostic value of FDG and amyloid PET in Alzheimer's disease-A systematic review.
Rice L; Bisdas S
Eur J Radiol; 2017 Sep; 94():16-24. PubMed ID: 28941755
[TBL] [Abstract][Full Text] [Related]
23. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
Fleisher AS; Chen K; Liu X; Roontiva A; Thiyyagura P; Ayutyanont N; Joshi AD; Clark CM; Mintun MA; Pontecorvo MJ; Doraiswamy PM; Johnson KA; Skovronsky DM; Reiman EM
Arch Neurol; 2011 Nov; 68(11):1404-11. PubMed ID: 21747008
[TBL] [Abstract][Full Text] [Related]
24. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
[TBL] [Abstract][Full Text] [Related]
25. Psychosocial and Behavioral Outcomes for Persons With Cognitive Impairment and Caregivers Following Amyloid-β PET Scan Disclosure: A Systematic Review.
Couch E; Ashford MT; Zhang W; Prina M
Alzheimer Dis Assoc Disord; 2023 Jul-Sep 01; 37(3):246-258. PubMed ID: 37561950
[TBL] [Abstract][Full Text] [Related]
26. Longitudinal tau PET in ageing and Alzheimer's disease.
Jack CR; Wiste HJ; Schwarz CG; Lowe VJ; Senjem ML; Vemuri P; Weigand SD; Therneau TM; Knopman DS; Gunter JL; Jones DT; Graff-Radford J; Kantarci K; Roberts RO; Mielke MM; Machulda MM; Petersen RC
Brain; 2018 May; 141(5):1517-1528. PubMed ID: 29538647
[TBL] [Abstract][Full Text] [Related]
27. Perspectives From Black and White Participants and Care Partners on Return of Amyloid and Tau PET Imaging and Other Research Results.
Rahman-Filipiak A; Lesniak M; Sadaghiyani S; Roberts S; Lichtenberg P; Hampstead BM
Alzheimer Dis Assoc Disord; 2023 Oct-Dec 01; 37(4):274-281. PubMed ID: 37890053
[TBL] [Abstract][Full Text] [Related]
28. Preferences regarding disclosure of a diagnosis of dementia: a systematic review.
van den Dungen P; van Kuijk L; van Marwijk H; van der Wouden J; Moll van Charante E; van der Horst H; van Hout H
Int Psychogeriatr; 2014 Oct; 26(10):1603-18. PubMed ID: 24933479
[TBL] [Abstract][Full Text] [Related]
29. Ethical Arguments Concerning the Use of Alzheimer's Disease Biomarkers in Individuals with No or Mild Cognitive Impairment: A Systematic Review and Framework for Discussion.
Smedinga M; Tromp K; Schermer MHN; Richard E
J Alzheimers Dis; 2018; 66(4):1309-1322. PubMed ID: 30507575
[TBL] [Abstract][Full Text] [Related]
30. PET imaging of brain amyloid in dementia: a review.
Quigley H; Colloby SJ; O'Brien JT
Int J Geriatr Psychiatry; 2011 Oct; 26(10):991-9. PubMed ID: 21905095
[TBL] [Abstract][Full Text] [Related]
31. Amyloid and Tau Biomarkers in Subjective Cognitive Impairment.
Colijn MA; Grossberg GT
J Alzheimers Dis; 2015; 47(1):1-8. PubMed ID: 26402749
[TBL] [Abstract][Full Text] [Related]
32. Cortical Amyloid Burden Differences Across Empirically-Derived Mild Cognitive Impairment Subtypes and Interaction with APOE ɛ4 Genotype.
Bangen KJ; Clark AL; Werhane M; Edmonds EC; Nation DA; Evangelista N; Libon DJ; Bondi MW; Delano-Wood L;
J Alzheimers Dis; 2016 Mar; 52(3):849-61. PubMed ID: 27031472
[TBL] [Abstract][Full Text] [Related]
33. A biomarker study in long-lasting amnestic mild cognitive impairment.
Cerami C; Dodich A; Iannaccone S; Magnani G; Santangelo R; Presotto L; Marcone A; Gianolli L; Cappa SF; Perani D
Alzheimers Res Ther; 2018 Apr; 10(1):42. PubMed ID: 29695292
[TBL] [Abstract][Full Text] [Related]
34. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes.
Schreiber S; Landau SM; Fero A; Schreiber F; Jagust WJ;
JAMA Neurol; 2015 Oct; 72(10):1183-90. PubMed ID: 26280102
[TBL] [Abstract][Full Text] [Related]
36. The psychological impact of disclosing amyloid status to Japanese elderly: a preliminary study on asymptomatic patients with subjective cognitive decline.
Wake T; Tabuchi H; Funaki K; Ito D; Yamagata B; Yoshizaki T; Kameyama M; Nakahara T; Murakami K; Jinzaki M; Mimura M
Int Psychogeriatr; 2018 May; 30(5):635-639. PubMed ID: 29094656
[TBL] [Abstract][Full Text] [Related]
37. Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants.
Harkins K; Sankar P; Sperling R; Grill JD; Green RC; Johnson KA; Healy M; Karlawish J
Alzheimers Res Ther; 2015; 7(1):26. PubMed ID: 25969699
[TBL] [Abstract][Full Text] [Related]
38. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
J Alzheimers Dis; 2018; 62(1):399-408. PubMed ID: 29439345
[TBL] [Abstract][Full Text] [Related]
39. Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review.
Petrou M; Dwamena BA; Foerster BR; MacEachern MP; Bohnen NI; Müller ML; Albin RL; Frey KA
Mov Disord; 2015 Jun; 30(7):928-35. PubMed ID: 25879534
[TBL] [Abstract][Full Text] [Related]
40. Utility of Amyloid and FDG-PET in Clinical Practice: Differences Between Secondary and Tertiary Care Memory Units.
Lage C; Suarez AG; Pozueta A; Riancho J; Kazimierczak M; Bravo M; Jimenez Bonilla J; de Arcocha Torres M; Quirce R; Banzo I; Vazquez-Higuera JL; Rabinovici GD; Rodriguez-Rodriguez E; Sánchez-Juan P
J Alzheimers Dis; 2018; 63(3):1025-1033. PubMed ID: 29710706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
